Transcode Therapeutics, Inc. Earnings Per Share Diluted

• Transcode Therapeutics, Inc. showed an increase of +98.6% in Earnings Per Share Diluted from 2023 to 2024.
• This data is from Transcode Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
• XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2020: $0.03 (loss) per share | Q1 2021: $0.97 (loss) per share | Q2 2021: $0.51 per share | Q3 2021: $0.20 (loss) per share | Q1 2022: $0.27 (loss) per share | Q2 2022: $7.20 (loss) per share | Q3 2022: $6.61 (loss) per share | Q1 2023: $259.07 (loss) per share | Q2 2023: $142.38 (loss) per share | Q3 2023: $48.44 (loss) per share | Q1 2024: $21.35 (loss) per share | Q2 2024: $680.23 (loss) per share | Q3 2024: $146.06 (loss) per share | Q1 2025: $2.51 (loss) per share | Q2 2025: $5.13 (loss) per share | Q3 2025: $5.82 (loss) per share.
• Over the full 5 years of available data (2020 to 2024), Transcode Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 9,143.1%.
• Historical annual values: Fiscal year 2024: $47.14 (loss) per share | Fiscal year 2023: $3,419.01 (loss) per share | Fiscal year 2022: $1,082.79 (loss) per share | Fiscal year 2021: $0.81 (loss) per share | Fiscal year 2020: $0.51 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026